Emma Walmsley, who in 2017 became the first woman to lead a major pharmaceutical company, will step down from her post as CEO ...
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with ...
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top ...
The centerpiece of the acquisition is petosemtamab, Merus’ bispecific antibody targeting EGFR and LGR5, which in May ...
Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Friday, means it has indeed ...
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory ...
By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
In one of the first demonstrations of the impact of last year’s Loper Supreme Court decision on challenges to agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback